The FDA Didn't Approve Six Peptides. Here's What Actually Happened.

If you follow this space, you have probably seen headlines suggesting the FDA cleared six peptides. That is not what happened, and the gap between the reporting and the record is worth understanding.

What actually happened

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee met at the agency's White Oak campus in Silver Spring, Maryland, to review seven peptides for the 503A Bulk Drug Substances List — the list governing which substances licensed compounding pharmacies may prepare for patients with a prescription.

The 14-member committee recommended six:

• BPC-157 — 8 yes, 6 no, 1 abstention
• KPV — 8 yes, 6 no
• TB-500 — 8 yes, 6 no
• MOTS-c — 7 yes, 5 no
• Semax — 8 yes, 5 no
• Epitalon — recommended on a narrow vote

Emideltide, also known as DSIP, was rejected on a 6–7 vote — the only one of the seven not recommended.

Each peptide was evaluated against specific proposed medical indications, not general wellness use.

The part the headlines skip

The FDA's own scientists recommended against all seven. In briefing materials posted before the meeting, agency staff concluded the available studies were short, small, and insufficient to establish safety or effectiveness. The committee voted against that written recommendation in every case where it voted yes.

The votes were close. Not one was unanimous. Several passed by two.

Advisory committees advise. The PCAC does not set policy. The FDA is the final decisionmaker and is not obligated to follow the recommendation, though it is unusual for the agency to reject one.

Nothing changes without rulemaking. Adding a substance to the 503A list requires formal notice-and-comment rulemaking. Reporting on the meeting suggests that process takes at least a year.

Three events the market keeps treating as one

Much of the confusion comes from collapsing three separate legal steps into a single headline:

1. Removal from Category 2 — happened in April 2026, when twelve peptides came off the restricted list after the original nominations were withdrawn.
2. A PCAC recommendation — happened in July 2026. Advisory only.
3. Actual placement on the compoundable list — has not happened, and requires rulemaking.

Only the third changes what a pharmacy may legally prepare.

What it does not mean

It does not mean any of these peptides are FDA-approved. Compounding eligibility and drug approval are different standards entirely — a compounded preparation is not FDA-approved and is not required to demonstrate efficacy through the trial process an approved drug undergoes.

It does not mean the evidence changed. No new safety or efficacy data prompted the vote. The underlying research base is the same as it was in June.

And it does not change anything about research-use-only material. Compounding pharmacies preparing prescription products for named patients, and RUO material supplied for laboratory work, are separate regulatory channels. A change to one does not alter the other.

Context worth having

The meeting followed months of public pressure. In February 2026, HHS Secretary Robert F. Kennedy Jr. publicly raised the FDA's treatment of several peptide substances. In April the agency removed twelve peptides from its Category 2 restricted list. The July meeting was announced in a Federal Register notice that same month.

The committee's composition drew scrutiny before it convened. Reporting noted the reconstituted roster included more members who prescribe, produce, or promote peptides than previous iterations of the panel. One member said during the meeting that she was concerned the committee was "responding to market induced demand rather than a decision based in solid science." Another warned that consumers would read the vote as an endorsement regardless of what it technically was.

What to watch

1. Whether the FDA accepts or rejects the recommendation. Its scientific staff already argued against it.
2. Whether HHS acts independently. Legal commentators have noted that Section 503A(c) may offer a faster route than rulemaking.
3. Whether further peptides go before the committee. The July meeting was described as the first in a series.

The honest summary

A narrowly divided advisory committee made a non-binding recommendation that the FDA's own scientists opposed. It is a real signal about where policy pressure is heading. It is not a decision, not an approval, and not a change in what the evidence shows.

---

Avera Refined Wellness supplies research-use-only compounds for in-vitro laboratory research. Nothing in this article is medical advice, and nothing on this site is intended to diagnose, treat, cure, or prevent any disease. Our products are not for human or veterinary use.